Why is it Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on the Global Oncology Diagnostics in IVD Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Scope of the Study

Segmentation by Test Type

Segmentation by Cancer Type

Segmentation by Application

Patient Care Continuum

Role of Oncology Diagnostics in Precision Medicine

The Role of Diagnostics is Crucial in the Evolving Precision Medicine Ecosystem

Trends Driving Cancer Testing

Growth Metrics

Growth Drivers

Growth Restraints

Key Oncology Diagnostics Opportunities and the Impact on Business Dynamics

Oncology Incidence Rate

Oncology Incidence Rate (continued)

Age-standardized Global Incidence Rates Per Sex—Top 10 Cancers

Forecast Assumptions

Revenue Forecast

Revenue Forecast Analysis

Revenue Forecast Analysis (continued)

Revenue Forecast by Region

Revenue Forecast Analysis by Region

Revenue Forecast Analysis by Region (continued)

Revenue Forecast Analysis by Region (continued)

Revenue Forecast Analysis by Region (continued)

HRSA’s Investment in the Accelerating Cancer Screening Program (the United States)

HRSA’s Investment in the Accelerating Cancer Screening Program (the United States) (continued)

Revenue Forecast by Test Type

Revenue Forecast Analysis by Test Type

Revenue Forecast Analysis by Test Type (continued)

Revenue Forecast by Cancer Type

Revenue Forecast Analysis by Cancer Type

Revenue Forecast Analysis by Cancer Type (continued)

Revenue Forecast Analysis by Cancer Type (continued)

Revenue Forecast Analysis by Cancer Type (continued)

Revenue Forecast Analysis by Cancer Type (continued)

Revenue Forecast Analysis by Cancer Type (continued)

Revenue Forecast Analysis by Cancer Type (continued)

Revenue Forecast Analysis by Cancer Type (continued)

Revenue Forecast Analysis by Cancer Type (continued)

Overview of Oncology Diagnostic Test Reimbursement by Region

Overview of Oncology Diagnostic Test Reimbursement by Region (continued)

Overview of Oncology Diagnostic Test Reimbursement by Region (continued)

Overview of Oncology Diagnostic Test Reimbursement by Region (continued)

Revenue Forecast by Application

Revenue Forecast Analysis by Application

Revenue Forecast Analysis by Application (continued)

Revenue Forecast Analysis by Application (continued)

Competitive Environment

Key Competitors

Revenue Share by Tier

Companies to Watch—QIAGEN

Companies to Watch—Roche Diagnostics

Companies to Watch—Guardant Health

Companies to Watch—Myriad Genetics

Companies to Watch—Genomic Health

Companies to Watch—PerkinElmer

Companies to Watch—Invitae Corporation

Companies to Watch—Abbott Laboratories

Companies to Watch—Illumina

Companies to Watch—Natera

Global Oncology Diagnostics Market: Notable Activities

Global Oncology Diagnostics Market: Notable Activities (continued)

Global Oncology Diagnostics Market: Notable Activities (continued)

Competitive Mapping by Application

Competitive Mapping by Application (continued)

Oncology Diagnostic Participants: Competitive Benchmarking

Oncology Diagnostic Participants: Competitive Benchmarking (continued)

Oncology Diagnostic Participants: Competitive Benchmarking (continued)

Oncology Diagnostic Participants: Competitive Benchmarking (continued)

Oncology Diagnostic Participants: Competitive Benchmarking (continued)

Oncology Diagnostic Participants: Competitive Benchmarking (continued)

Global Oncology Diagnostics Companies: Strategic Imperatives

CDx Overview

CDx Market Trends

CDx Global Reimbursement Overview

CDx Reimbursement Challenges

CDx FDA Approvals for Oncology Drugs and Biomarkers

CDx FDA Approvals for Oncology Drugs and Biomarkers (continued)

CDx FDA Approvals for Oncology Drugs and Biomarkers (continued)

CDx Targets by Company

Companion Diagnostic Partnerships

List of FDA-cleared/approved Companion Diagnostic IVD Devices

List of FDA-cleared/approved Companion Diagnostic IVD Devices (continued)

List of FDA-cleared/approved Companion Diagnostic IVD Devices (continued)

List of FDA-cleared/approved Companion Diagnostic IVD Devices (continued)

List of FDA-cleared/approved Companion Diagnostic IVD Devices (continued)

List of FDA-cleared/approved Companion Diagnostic IVD Devices (continued)

Liquid Biopsy: A Step Ahead in Biomarker Analysis

Potential of Liquid Biopsies to Improve Screening and Triage Pathways

miRNAs as Potential Cancer Biomarkers

miRNAs as Potential Cancer Biomarkers (continued)

miRNAs as Potential Cancer Biomarkers (continued)

miRNAs as Potential Cancer Biomarkers (continued)

miRNAs as Potential Cancer Biomarkers (continued)

Liquid Biopsy Companies in the Industry

Liquid Biopsy Regulatory Landscape

FDA-approved Liquid Biopsy Tests

Liquid Biopsy Technology and Recent Developments

Liquid Biopsy Technology and Recent Developments (continued)

Advancing Liquid Biopsies: Embracing Multiomics for Comprehensive Insights

Liquid Biopsy Market Opportunities

Liquid Biopsy Commercialization

Growth Opportunity Summary

Growth Opportunity 1: Growing Trend of Oncology Screening

Growth Opportunity 1: Growing Trend of Oncology Screening (continued)

Growth Opportunity 2: Advanced, Integrated Diagnostics Labs

Growth Opportunity 2: Advanced, Integrated Diagnostics Labs (continued)

Growth Opportunity 3: Increased Adoption of Liquid Biopsy Testing

Growth Opportunity 3: Increased Adoption of Liquid Biopsy Testing (continued)

Growth Opportunity 3: Increased Adoption of Liquid Biopsy Testing (continued)

Growth Opportunity 4: Smart Diagnostics with AI

Growth Opportunity 4: Smart Diagnostics with AI (continued)

Growth Opportunity 4: Smart Diagnostics with AI (continued)

Growth Opportunity 5: Unlocking CDx Opportunities in APAC

Growth Opportunity 5: Unlocking CDx Opportunities in APAC (continued)

Growth Opportunity 5: Unlocking CDx Opportunities in APAC (continued)

Growth Opportunity 6: Unleashing Opportunities in Lung Cancer Diagnostics and Screening

Growth Opportunity 6: Unleashing Opportunities in Lung Cancer Diagnostics and Screening (continued)

Your Next Steps

Why Frost, Why Now?

List of Exhibits

Legal Disclaimer